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Abstract: Ciclesonide is a novel inhaled corticosteroid used in the continuous treatment of 
mild-to-severe asthma. Its formulation and mechanism of action yield a low oral and systemic 
bioavailability, and high pulmonary deposition. In multiple clinical trials, ciclesonide is at least 
as effective as either ﬂ  uticasone propionate or budesonide at symptom control, while in many 
cases having improved safety outcomes and tolerability. The improved safety and comparable 
efﬁ  cacy proﬁ  les of ciclesonide demonstrated in current studies could potentially yield a treatment 
option that may lead to improved adherence and outcome.
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Introduction
Asthma poses a signiﬁ  cant burden to society in terms of morbidity, mortality, quality 
of life, and healthcare costs.1–3 Among children, asthma rates in the United States 
are currently at record highs, with a nationwide prevalence of approximately 9% of 
children aged 1 to 17 years.3 Its burden on the economy is estimated at between US$4 
to 6 billion annually, considering healthcare costs and lost work days for caregivers 
and patients alike.4 Inhaled corticosteroids (ICS) are recommended as ﬁ  rst-line therapy 
for the treatment of asthma,5,6 and can improve both asthma symptomatology and 
the markers of airway inﬂ  ammation.7–9 However, despite being demonstrated as an 
efﬁ  cacious controller therapy, concerns remain regarding the potential for adverse 
side effects associated with chronic ICS treatment. Speciﬁ  cally, some ICS molecules 
have been demonstrated to cause reductions in growth velocity9–11 and bone mineral 
density,12,13 HPA-axis suppression,14,15 and oral candidiasis.16,17
Ciclesonide (Alvesco®; Sepracor, Inc., Nycomed, Inc.) is a novel, new corticoste-
roid developed for the treatment of mild to severe persistent asthma. It is delivered by 
metered-dose inhaler (MDI) once daily or twice daily (dosing depends on country). 
This review will focus on the safety and efﬁ  cacy proﬁ  le of ciclesonide, as well as to 
establish its mechanism of action.
Mechanism of action
Ciclesonide ([R]-11β, 16α, 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 
16,17-acetal with cyclohexanecarboxaldehyde 21-isobutyrate; CIC) is inhaled into the 
lungs via hydroﬂ  uoroalkane-MDI (HFA-MDI), where it is converted by local ester-
ases to its active metabolite, desisobutyryl-ciclesonide (des-CIC, Figure 1). Relative 
to dexamethasone (100), CIC has a low glucocorticoid receptor binding afﬁ  nity 
of 12, while des-CIC has a signiﬁ  cantly higher binding afﬁ  nity of 1212.18,19 Studies 
demonstrate no conversion of R-CIC or des-CIC to the S-epimer in vivo, which 
has different physicochemical properties, and a markedly lower receptor afﬁ  nity.20 
Pharmacokinetic proﬁ  les of des-CIC were similar in comparative healthy and asthma 
patients, likely indicating that bronchial narrowing and airway inﬂ  ammation do 
not affect the distribution of CIC and its subsequent activation to des-CIC in the Journal of Asthma and Allergy 2009:2 26
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lungs.21 An additional study also demonstrated equivalent 
PK/PD proﬁ  les of CIC-HFA when administered with and 
without a spacer.22
In vitro data indicate metabolism of des-CIC was dif-
ferent in precision-cut human lung and liver tissue slices.23 
After 24 hours incubation with [14C]-CIC, 7.2 times more 
radioactivity was present in the lung tissue, as compared 
with the liver. Furthermore, in the lung tissue [14C]-CIC 
was converted to des-CIC and subsequently conjugated with 
fatty acid metabolites, a reversible process which increases 
lipophilicity of des-CIC and may result in prolonged 
drug retention and anti-inﬂ  ammatory activity in the lung 
(Figure 2).23,24 Alternatively, [14C]-CIC was catabolically 
inactivated in liver tissue into at least 5 different polar 
compounds, with dihydroxylated des-CIC being the major 
metabolite.23 Additionally, other ﬁ  ndings demonstrated that 
orally and intravenous-administered [14C]-CIC resulted in a 
negligible serum concentration of des-CIC and no accumula-
tion in red blood cells, indicating a low absorption and almost 
complete ﬁ  rst-pass metabolism (systemic bioavailability of 
des-CIC   1%).25
The demonstrated mean lung deposition of CIC is 
52%.26 The internal diameter of the smallest airways in 
adults are typically ∼2 μm, thus, it can be inferred that 
smaller ICS particles lead to greater pulmonary deposition 
and more even distribution throughout the lungs (Table 1). 
Accordingly, the HFA-MDI formulation of CIC contains 
a majority of ICS particles which range between 1.1 and 
2.1 μm.27,28 This particle size is likely related to the high 
observed pulmonary deposition of CIC.28 Furthermore, 
uptake of CIC, budesonide (BUD), and ﬂ  uticasone pro-
pionate (FP) in human alveolar type II epithelial cells 
(A549) was measured, and at all incubation timepoints, 
intracellular concentration of CIC was higher than that of 
BUD and FP.29 This indicates a more rapid uptake of CIC 
molecules into target tissue, and at a higher concentration. 
Additionally, separate in vitro data indicate intracellular 
concentration of des-CIC in A549 cells to be maintained 
for  20 hours.29
Efﬁ  cacy
Placebo-controlled
The therapeutic action of ciclesonide is achieved after the 
inhaled parent compound (CIC) is cleaved by esterases in 
the lungs to its active metabolite (des-CIC), a corticosteroid 
with high receptor afﬁ  nity and anti-inﬂ  ammatory activ-
ity.18,19,30 In a randomized, double-blind trial, early (EAR) 
and late (LAR) phase allergen-induced asthmatic reactions 
were signiﬁ  cantly inhibited (p   0.05) by treatment with 
CIC, versus placebo (as evaluated by decrease in FEV1 
following allergen challenge).31 These anti-imﬂ  ammatory 
properties were also exhibited in vitro, as CIC attenuated 
EAR/LAR, inﬁ  ltration of inﬂ  ammatory cells into bronchoal-
veolar lumen, and airway hyperresponsiveness in sensitized 
Brown Norway rats.32 These effects were observed in a 
dose-dependent manner.
These anti-inﬂ  ammatory properties have been noted 
in patients with mild, persistent asthma, treated with CIC 
160 μg (all doses noted in this review are ex-actuator) 
once-daily over a period of 4 weeks.33 Measurements were 
made before and after treatment in this double-blind study 
for adenosine monophosphate (AMP) bronchial challenge, 
and exhaled nitric oxide (eNO). Mean AMP challenge PC20 
following ciclesonide treatment was signiﬁ  cantly increased 
(p   0.001) compared to placebo, and decreases in eNO 
(ppb) and induced sputum eosinophil cell counts were also 
noted.33 Additionally, Bateman et al34 demonstrated the 
effectiveness of CIC 320 μg and 640 μg in reducing oral 
corticosteroid use in adults with severe, persistent asthma, 
versus placebo.
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Figure 1 Molecular structure of ciclesonide and its activated metabolite, desisobutyryl-ciclesonide (des-CIC). Christie P. Ciclesonide: A novel inhaled corticosteroid for 
asthma. Drugs Today (Barc). 2004; 40(7):569–576.19 Copyright © 2004 Prous Science, S.A.U.   All rights reserved.Journal of Asthma and Allergy 2009:2 27
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Three double-blind studies demonstrated that treatment 
with CIC improves symptom control in patients who 
were previously treated with another ICS. O’Connor, 
et al35 demonstrated signiﬁ  cant improvement in FEV1 in 
moderate-to-severe asthmatics treated with either CIC 800 μg 
or 1600 μg daily, compared to placebo (12-week treatment, 
pretreatment with 800–2000 μg/day BDP). A similarly 
designed study by Langdon et al36 noted improvements in 
baseline FEV1 and morning PEF in subjects treated with CIC 
over a period of 12 weeks, but at more clinically-relevant 
doses (CIC 80 μg, 320 μg daily, versus placebo). Subjects 
were also previously treated with lower, constant doses of 
BDP or its equivalent (400–800 μg daily) for at least 4 weeks 
prior to randomization. Asthma control in previously treated 
subjects was maintained by CIC 160 μg or 640 μg once daily 
in another study by Chapman.37
In a large, double-blind, 12-week study (n = 1031), 
Gelfand38 studied the effect of multiple strength doses of 
CIC (40 μg, 80 μg, or 160 μg) on children aged 4 to 11 with 
mild to severe persistent asthma. Following run-in, subjects 
were randomized to one of three once-daily CIC treatments, 
or placebo. All CIC doses were associated with signiﬁ  cant 
increases in FEV1 compared to placebo at study endpoint 
(CIC 40 μg, 11.91; CIC 80 μg, 13.58; CIC 160 μg, 14.17). 
Reductions in rescue medication use within study treatment 
cohorts were also reported.
Comparative studies
Once-daily dosing of CIC (which is approved in some, but 
not all countries) is a signiﬁ  cant distinction between it and 
other common ICS for treatment of asthma, such as BUD 
and FP. Currently, there have not been any comparative 
efﬁ  cacy trials between CIC and mometasone furoate, another 
commonly used ICS which is approved for once-daily dosing; 
future studies should directly compare efﬁ  cacy of these two 
agents. CIC has demonstrated efﬁ  cacy with a single daily 
dose,33–42 as well as when administered either in the morning 
or evening.39 The effectiveness of a single daily dose could 
lead to improved compliance and symptom control in patients 
using CIC as asthma control therapy.
CIC comparative efﬁ  cacy trials are summarized in Table 2. 
Ukena43 demonstrated CIC 320 μg once daily to be superior 
to BUD 200 μg twice-daily in increasing FEV1 from baseline 
(416 mL in CIC versus 321 mL in BUD; p = 0.019, 95% CI). 
While improvements were seen in FVC for both cohorts, a 
signiﬁ  cantly larger difference was seen in CIC-treated subjects. 
Additionally, significant improvement versus baseline in 
morning PEF was seen after Day 2 in the CIC cohort (p = 0.039 
versus baseline) and Day 7 in the BUD cohort (p = 0.047 versus 
baseline), indicating a more rapid onset of action for CIC.
However, these ﬁ  ndings appear to be an outlier, as the 
majority of trials have found CIC at least as effective as 
BUD (Turbuhaler®/DPI) in controlling asthma, in vary-
ing subject populations and disease severities.44–48 FEV1 
improvement was noted in these studies with both BUD 
and CIC, and no signiﬁ  cant between-group differences 
were noted. Pediatric Asthma Quality of Life Questionnaire 
(PAQLQ) and Pediatric Asthma Caregiver’s Quality of Life 
Questionnaire (PACQLQ) scores were similarly improved 
Table 1 Characteristics of ciclesonide
Method of delivery HFA-MDI
Particle size27 1.1–2.1 μm
Pulmonary Deposition26 52%
Oral deposition26 38%
Systemic bioavailability30 CIC = 18% Des-CIC = 50%
Serum protein binding (des-CIC)62 ∼99%,  1% unbound fraction
Target tissue retention (des-CIC)25  24 hours
Mean terminal half-life (t1/2; des-CIC)27 3.5 hours
Elimination half-life (t1/2; CIC)27 0.71 hours
Abbreviations: CIC, ciclesonide; des-CIC, desisobutyryl-ciclesonide; HFA-MDI, 
hydroﬂ  uoroalkane metered dose inhaler.
Figure 2 Intracellular activation of ciclesonide and reversible esteriﬁ  cation of 
desisobutyryl-ciclesonide (des-CIC). Ciclesonide is activated by intracellular esterases 
to active metabolite, des-CIC, which has high afﬁ  nity to the glucocorticosteroid (GCS) 
receptor. Desisobutyryl-ciclesonide can undergo reversible esteriﬁ  cation to des-CIC 
oleate (fatty acid ester). Reprinted with permission from Nave R, Meyer W, Fuhst R, 
Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat 
lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18:390–396.62 
Copyright © 2005 Elsevier.Journal of Asthma and Allergy 2009:2 28
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over a 12-week study comparing CIC 160 μg once daily 
to BUD 400 μg once daily.47 Some modest beneﬁ  t was 
seen for CIC, with Boulet45 ﬁ  nding a greater percentage 
of symptom-free days for CIC (43%) than BUD (34%; 
p = 0.0288), but overall, both ICS seem to be comparably 
efﬁ  cacious. Similarly, comparative studies between CIC 
and FP show clear non-inferiority of CIC.40–42,49–51 No 
difference in comparative efﬁ  cacy was observed when com-
paring CIC to both FP-DPI49 and FP-MDI.40–42,50,51 FP and 
CIC were equally effective at maintaining asthma control 
in subjects who were on continuous ICS therapy prior to 
randomization.40,50
Safety and tolerability
Oral candidiasis
Considering CIC is relatively inactive, and is converted to 
active des-CIC in the lungs versus some conversion in the 
oral cavity, this proﬁ  le would suggest a lower oropharyngeal 
deposition and frequency of side effects (ie, candidiasis). 
Indeed, comparative studies indicate low deposition and 
Table 2 Ciclesonide comparative efﬁ  cacy trials
Author/citation Dosing Subject characteristics Treatment duration Outcome
Knox40, 2007 CIC 160 μg qd; 
FP 250 μg bid
17–75 y; controlled asthma 
w/pretreatmenta
2-week baseline w/ 
current ICS, 12 week 
treatment
CIC and FP had similar FEV1 
maintenance and symptom-free 
days
Lee41, 2004 CIC 160 μg qd; 
FP 110 μg bid; placebo
mild to moderate asthmatics separate 4 week treatment 
arms, separated by 2-week 
washout w/ salmeterol + 
montelukast
No difference between 
groups in methacholine PC20 
hyperresponsiveness
Buhl42, 2006 CIC 160 μg qd; 
FP 88 μg bid
12–74 y; mild to moderate 
asthma (GINA)
1- to 2-week baseline w/ 
rescue med only; 12-week 
treatment
CIC and FP similarly improved 
lung function, symptom scores, 
and rescue med use. During 
last 4 weeks, CIC had higher 
percentage of symptom-free days
Niphadkar44, 2005 CIC 160 μg qd; 
BUD 200 μg bid
adults w/ FEV1   70%, pretreated 12 weeks, 2-week run-in 
w/BUD 200 μg bid
CIC as effective as BUD 
at symptom control
Boulet45, 2006 CIC 320 μg qd; 
BUD 200 μg bid
pretreated, FEV1 inc.   7% and 
65%–90% pred. after run-in
2-week baseline w/ BUD 
1600 μg qd, 12-week 
treatment
CIC qd as effective as BUD bid
Hansel46, 2006 CIC 80 μg qd; 
CIC 320 μg qd; 
BUD 200 μg bid
FEV1 50%–90% pred. 12 weeks CIC and BUD improved FEV1, 
FVC, and PEF similarly
von Berg47, 2007 CIC 160 μg qd; 
BUD 400 μg qd
children w/moderate to severe 
asthma (GINA 1995)
2- to 4-week run-in 
w/rescue med only, 
12 week treatment
CIC and BUD similarly 
improved FEV1, morning PEF, 
rescue med use, and QoL 
scores
Vermeulen48, 2007 CIC 320 μg qd;
 BUD 800 μg qd
Children 12–17 y w/severe 
asthma (GINA 1995)
2-week baseline w/BUD 
400 μg qd, 
12-week treatment
CIC and BUD comparably 
improved FEV1, FVC, PEF, 
symptom-free days, and rescue 
med use
Boulet49, 2007 CIC 320 μg qd; 
FP 200 μg bid
12–75 y; FEV1   80% 
w/pretreatment, or FEV1 
60–80 and pred
1- to 4-week run-in, 
12-week treatment
CIC and FP similarly increased 
FEV1 and resulted in comparable 
numbers of symptom-free days
Bateman50, 2008 CIC 320 μg bid; 
FP 330 μg bid
12–75 y; moderate to severe 
controlled asthma 
w/pretreatment
2-week baseline w/ 
current ICS, 24-week 
treatment
CIC and FP maintained FEV1, 
and improved morning/evening 
PEF, rescue med use, and QoL 
scores
Pedersen51, 2006 CIC 80 μg bid; 
FP 88 μg bid
symptomatic children 6–15 y; 
FEV1 50%–90% pred
2- to 4-week baseline w/ 
rescue med only; 12-week 
treatment
CIC and FP similarly improved 
FEV1, morning/evening PEF, 
rescue med usage, and reported 
symptoms
aPretreatment deﬁ  ned as subjects having daily ICS treatment prior to randomization.   All doses noted are ex-actuator.
Abbreviations: BUD, budesonide; CIC, ciclesonide; FP, ﬂ  uticasone propionate; ICS, inhaled corticosteroids.Journal of Asthma and Allergy 2009:2 29
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activated des-CIC within the oropharynx. Two similarly 
designed studies compared CIC to FP52 and BUD53, using 
mouthwash solutions containing 50% ethanol at 5 time 
points (immediate, 15, 30, 45, and 60 minutes after inhala-
tion) to compare deposition. The sum of CIC and des-CIC 
molar AUCs0–60 min was 53% (95% CI: 40%–69%) of FP 
deposition52 and 47% of the BUD deposition.53 Furthermore, 
oral deposition of des-CIC was less than 10% that of FP 
and BUD.
Incidence of candidiasis from continuous ICS treatment 
is a concern, and a common reason for poor adherence, and 
in some cases, not beginning an asthma patient on an ICS 
treatment regimen.16 For example, in one of the aforemen-
tioned efﬁ  cacy studies, 9 cases of candidiasis were noted 
(over a 12-week treatment period) among subjects receiving 
FP 200 μg twice-daily, compared to no reported cases in sub-
jects treated with CIC 320 once-daily.49 Likewise, Gelfand38 
found the incidence of oral candidiasis and pharyngitis over 
a 12-week treatment period with CIC 40 μg, 80 μg, and 
160 μg to be not signiﬁ  cantly different from placebo. This 
ﬁ  nding is consistent with that of Pearlman,54 who found 
incidences of oropharyngeal side effects similar to placebo 
in patients treated with CIC 80 μg, 160 μg, or 320 μg over 
the same duration.
HPA-axis function
Concerns of ICS acting as endogenous glucocorticoids, 
thereby suppressing the HPA-axis, have resulted in reluctance 
of some physicians to prescribe such a treatment continu-
ously. CIC has high protein binding and high systemic clear-
ance, a proﬁ  le that would seem to minimize interference with 
normal HPA-axis function. In one double-blind, randomized, 
crossover trial, Agertoft55 studied children aged 6 to 12 years 
who were given placebo, CIC 40 μg, 80 μg, or 160 μg once 
daily during four 2-week treatment periods, followed by 
2-week washouts. Analysis of 12 hours urinary cortisol at the 
end of each treatment period yielded no signiﬁ  cant between-
group differences or dose-response effects. This is of interest 
because these subjects were given clinically relevant doses 
of CIC for their age and disease severity.
Vermeulen et al48 found that over 12 weeks of treatment 
in children, CIC 320 μg once-daily was not associated with 
a signiﬁ  cant decrease in 24 urinary free cortisol (Δ = +1.05; 
nmol/mmol), while BUD 800 μg once daily was (Δ = −2.63). 
This between-group difference was signiﬁ  cant (p = 0.003). 
Adult patients (n = 60,  18 years) in a separate study were 
randomized to receive CIC 320 μg or 640 μg twice daily, FP 
440 μg or 880 μg twice daily (CFC-MDI), or placebo. Neither 
CIC nor FP treatment was associated with a signiﬁ  cant 
change in mean serum cortisol AUC0–24 h at these clinically 
relevant doses.56 Alternatively, a study by Lipworth et al 
using the same comparative doses of FP and CIC, found 
evidence of adrenal suppression by FP, using cosyntropin-
stimulated peak serum cortisol levels to analyze HPA-axis 
function.57
Noteworthy is that this pattern of adrenal safety continued 
even when CIC was administered in doses higher than would 
normally be used in clinical practice. Derom et al58 concluded 
that doses as high as CIC 640 μg twice daily had no sig-
niﬁ  cant effect on mean urinary cortisol levels (AUC0–24 h), 
while FP 440 μg and 880 μg twice daily suppressed them 
by 29% (95% CI, 15–41), compared with placebo. Decreases 
in PC20 hyperresponsiveness were similar in all cohorts.58 
In the previously mentioned study by Szeﬂ  er,56 serum and 
urinary cortisol suppression was associated with high-dose 
FP 2000 μg daily, but not with CIC 1600 μg daily.56 Again, 
airway outcomes (PC20 hyperresponsiveness, exhaled nitric 
oxide) were improved with both treatments.
Growth effects
The effects of continuous CIC treatment on childhood 
growth velocity have been studied. Knemometry, though 
not a predictor of long-term growth velocity or ﬁ  nal adult 
height, is an extremely sensitive measure of short-term 
changes in lower-leg growth. This method was utilized by 
Agertoft55 to determine if 2-week treatment with CIC 40 μg, 
80 μg, and 160 μg once daily resulted in any short-term 
changes in growth velocity. Lower leg growth rates for 
CIC were not signiﬁ  cantly different from placebo, and no 
dose-response effects were noted (placebo: 0.412 mm/week; 
CIC 40: 0.425 mm/week; CIC 80: 0.397 mm/week; CIC 160: 
0.370 mm/week).
To date, the only long-term assessment of growth velocity 
in children treated with CIC was completed by Skoner 
et al59 where height was assessed by stadiometry. Children 
(n = 661) aged 5 to 8½ years were randomized to receive 
placebo, CIC 40 μg, or CIC 160 μg once daily, for a treatment 
period of 1 year. Mean differences in yearly height from 
placebo (5.75 cm/year) were nonsigniﬁ  cant (−0.02 cm/year 
for CIC 40 and −0.15 cm/year for CIC 160), illustrating the 
noninferiority of CIC for growth velocity, when compared 
to placebo (Figure 3).59 Ideally, a study similar to that of 
Agertoft and Pedersen,60 which determined children treated 
with BUD eventually reached normal adult height despite 
some initial reduction in growth velocity, should be per-
formed with CIC.Journal of Asthma and Allergy 2009:2 30
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Figure 3 Subjects in all cohorts (CIC40, CIC160, placebo) achieved virtually the same growth velocity during one year of continuous CIC treatment. Reprinted with permission 
from Skoner DP, Maspero J, Banerji D, and the Ciclesonide Pediatric Growth Study Group.   Assessment of the Long-term Safety of Inhaled Ciclesonide on Growth in Children 
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Conclusion
From the evidence currently available, CIC appears to be 
a novel, safe, and efﬁ  cacious ICS for use in the continuous 
treatment of asthma. The low oral bioavailability can likely 
be attributed to the low afﬁ  nity of CIC to glucocorticoid 
receptors, as compared to its active metabolite, des-CIC, 
which is activated in the lungs. des-CIC is highly lipid con-
jugated in the lungs, allowing for greater retention in target 
tissues, and clinically, once-daily dosing (in at least some 
patients). While these pharmacokinetic properties result in 
an efﬁ  cacious ICS, they directly contribute to the noticeably 
enhanced safety proﬁ  le of CIC, especially in comparison 
with other ICS molecules, such as BUD and FP. High 
protein binding and the aforementioned receptor afﬁ  nity of 
CIC result in low systemic bioavailability, and potentially 
explain the low occurrence of adverse events such as candi-
diasis, adrenal suppression, and growth velocity disturbance. 
Comparative studies indicate the effectiveness of CIC to be 
similar to that of FP and BUD, but with an improved safety 
proﬁ  le, indicating the potential of this alternative treatment 
option in patients concerned about the risks of continuous 
ICS treatment. Minimizing risk of treatment while maintain-
ing efﬁ  cacy is a top clinical priority to improve treatment 
adherence and gain optimal outcome of therapy.
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